Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares reached a new 52-week high and low during trading on Friday . The stock traded as low as $1.98 and last traded at $1.99, with a volume of 1487928 shares traded. The stock had previously closed at $2.07.
Several research analysts have recently commented on CLDX shares. BidaskClub lowered Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, January 11th. Cantor Fitzgerald reiterated a “buy” rating and issued a $9.00 price objective on shares of Celldex Therapeutics in a research note on Wednesday, March 7th. HC Wainwright set a $10.00 price objective on Celldex Therapeutics and gave the company a “buy” rating in a research note on Friday, February 9th. Finally, Leerink Swann reiterated a “market perform” rating and issued a $3.00 price objective (down from $4.00) on shares of Celldex Therapeutics in a research note on Thursday, March 8th. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. Celldex Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $6.38.
The company has a market cap of $292.02, a PE ratio of -2.49 and a beta of 2.45.
Several hedge funds and other institutional investors have recently made changes to their positions in CLDX. Cubist Systematic Strategies LLC acquired a new stake in shares of Celldex Therapeutics in the third quarter valued at $101,000. OxFORD Asset Management LLP acquired a new stake in shares of Celldex Therapeutics in the third quarter valued at $122,000. Teacher Retirement System of Texas raised its stake in Celldex Therapeutics by 325.0% in the fourth quarter. Teacher Retirement System of Texas now owns 43,253 shares of the biopharmaceutical company’s stock valued at $123,000 after buying an additional 33,077 shares in the last quarter. MetLife Investment Advisors LLC acquired a new stake in Celldex Therapeutics in the fourth quarter valued at $187,000. Finally, Two Sigma Advisers LP acquired a new stake in Celldex Therapeutics in the fourth quarter valued at $238,000. Institutional investors and hedge funds own 55.49% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Celldex Therapeutics (CLDX) Reaches New 12-Month High and Low at $1.98” was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3339944/celldex-therapeutics-cldx-reaches-new-12-month-high-and-low-at-1-98.html.
About Celldex Therapeutics
Celldex Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma.
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.